Disc Medicine : Corporate Presentation

Corporate Presentation

February 2023

Disclaimer and FLS

This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include express or implied statements relating to Disc's management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc's current beliefs, expectations and assumptions regarding the future of Disc's business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or

implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Disc's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the adequacy of Disc's capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc's product candidates; Disc's plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc's planned preclinical studies and clinical trials; the timing of the availability of data from Disc's clinical trials; Disc's ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc's preclinical studies and clinical trials and the risk that the results of Disc's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; the other risks and uncertainties described in the "Risk Factors" section of the Current Report on Form 8-K filed with the SEC on December 29, 2022, and other documents filed by Disc from time to time with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Disc's subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward- looking statement, whether as result of new information, future events or otherwise, except as required by law.

2

Disc is Building a Leading Company Dedicated

to Treating Hematologic Diseases

Focus on

Hematologic

Disorders

Immense medical need

across a wide spectrum of

disorders

Predictive, objective

endpoints

Fundamental

• Validated Pathways

Fundamental to red blood cell biology: iron and heme

Clinical and genetic evidence of target mechanism in humans

Multiple

Clinical

Programs with Broad Potential

Bitopertin in Phase 2

DISC-0974 in Phase 1b/2

New Program: MWTX-003

is Phase 1-Ready

Multiple

Near-Term

Catalysts

Data expected 2023:

Bitopertin in EPP

DISC-0974 in MF and NDD-

CKD

Initiate Ph 1 MWTX-003

EPP (Erythropoietic Protoporphyria); XLP (X-linked Protoporphyria); MF (myelofibrosis); NDD (non-dialysis dependent) CKD (chronic kidney disease)

3

Our Executive Team

Deep experience building companies and bringing therapies to patients

John Quisel, JD, PhD | CEO & President

Former EVP & Chief Business Officer at Acceleron Pharma; 14 years through transformative Celgene partnerships, IPO and launch of Reblozyl®; led re- acquisition and positioning of sotatercept for PAH

Joanne Bryce, CPA | Chief Financial Officer

Former CFO of Arkuda Therapeutics, Dyne Therapeutics, and Quartet Medicine; previously at WiTricity, Speedy Packets, Narrative Communications; Arthur Andersen

Brian MacDonald, MB, ChB, PhD | Chief Innovation Officer

Founder and former Board Member of Disc Medicine; founder and CEO of Merganser Biotech; Previously at Zelos Therapeutics, 3-Dimensional Pharmaceuticals, GlaxoSmithKline

Jonathan Yu, MBA | Chief Business Officer

Qpex Biopharma (Co-founder), The Medicines Company, Acceleron Pharma, and Johnson & Johnson. Leadership roles in corporate strategy, finance and operations licensing, M&A, and commercial planning

Will Savage, MD, PhD | Chief Medical Officer

Magenta Therapeutics and Shire / Takeda; Trained in Pediatric Hematology & Transfusion Medicine; Faculty at Harvard Medical School, Johns Hopkins University School of Medicine

Rahul Khara, PharmD, JD | General Counsel

Former VP Legal and Chief Compliance Officer at Acceleron Pharma, supported commercial launch of Reblozyl® and eventual acquisition by Merck; Arnold & Porter, LLP; Sidley Austin LLP

Srikanth Venkatraman, PhD | SVP Chemistry

Merck and Schering-Plough, leadership roles in discovery, manufacturing and formulation, including for Victrelis® (boceprevir), first approved HCV protease inhibitor

Hua Yang, PhD | SVP Nonclinical R&D

Agios, Millennium / Takeda, BMS. Leadership positions in DMPK and Clinical Pharmacology, including for approved therapies IDHIFA® (enasidinib), TIBSOVO® (ivosidenib) and PYRUKIND® (mitapivat)

4

Min Wu, PhD | VP Biology

Proteostasis, FORMA, Agios, AVEO Oncology. Discovery and development across range of therapeutic areas including oncology and orphan disease including AATD, CF, lysosomal storage disease and others

Jeremy Brinkerhoff, CPA | VP Finance

Former Partner at CFGI, a portfolio company of The Carlyle Group and largest non-audit accounting advisory firm in US and focused on life science companies; Covidien; PwC

Our Investors & Advisors

Supported by Top-Tier Healthcare Investors

Board of Directors				Scientific Advisory Board
Donald Nicholson, PhD	Kevin Bitterman, PhD	Liam Ratcliffe, MD, PhD		Mark Fleming, MD, DPhil	Stefano Rivella, PhD
Former CEO, Nimbus Therapeutics	Partner	Head of Biotechnology		Professor, Pathology	Professor, Pediatric Medicine
Chairman of the Board	Atlas Venture	Access Industries		Harvard Medical School	Chair, Sickle Cell Anemia, CHOP
Mona Ashiya, PhD	Mark Chin, MS, MBA	William White, JD		Tomas Ganz, MD, PhD	Uma Sinha, PhD
Partner	Managing Director	CFO, Akero Therapeutics		Professor, Medicine	CSO, Bridge Bio
OrbiMed	Arix Biosciences	Audit Committee Chair		UCLA	Former CSO, Global Blood Therapeutics
Jay Backstrom, MD, MPH	George Gemayel, PhD	John Quisel, JD, PhD		Elizabeta Nemeth, PhD	Srdan Verstovsek, MD, PhD
CEO and President	Former Executive Chair	CEO and President		Professor, Medicine	Professor, Medicine
Scholar Rock	Gemini Therapeutics	Disc Medicine		UCLA	U. Texas / MD Anderson

5